Dupilumab Improves Small Airway Dysfunction in People With Type 2 Asthma

Brian Lipworth, MD

Credit: University of Dundee

Dupilumab improved small airway dysfunction (SAD) in people with type 2 high moderate-to-severe asthma, possibly explaining improvements in disease control.¹

These findings, from the phase 4 VESTIGE study (NCT04400318), will be presented at the 2025 American Academy of Allergy, Asthma, and Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress, February 28-March 3, in San Diego, California, by Brian Lipworth, MD, Professor of Allergy and Pulmonology at University of Dundee.

“SAD measured by airway oscillometry is related to type 2 inflammation and poor asthma control. Here, we present a post hoc analysis of the phase 4 VESTIGE study evaluating the effects of dupilumab using airway oscillometry,” Lipworth and colleagues wrote.¹

The VESTIGE study enrolled adult…